Clopidogrel (SR-25990C) Bisulfate
For research use only.
Catalog No.S1415 Synonyms: Clopidogrel hydrogen sulfate, Iscover, Plavix
CAS No. 120202-66-6
Clopidogrel Bisulfate (SR-25990C, Clopidogrel hydrogen sulfate, Iscover, Plavix) is an oral, thienopyridine class antiplatelet agent.
Selleck's Clopidogrel (SR-25990C) Bisulfate has been cited by 5 publications
2 Customer Reviews
(A) HPLC glycan traces of IgG recovered from joint after K/BxN and PBS or B4ST6Fc treatment with or without clopidogrel. (B) Ratios of monosialylated and agalactosylated glycans (S1/G0) from IgG described in (A).
Cell, 2018, 172(3):564-577.e13. Clopidogrel (SR-25990C) Bisulfate purchased from Selleck.
C, The expression of EGFR in the clopidogrel‐ treated cells was analyzed by immunoblot analysis. The clopidogrel‐treated cells (HSC3 and SAS) show down‐regulation of FBLIM1 and EGFR compared with the control cells. D, The images of expression of EGFR after treatment with clopidogrel for 48 h analyzed by IF. Most EGFR is localized at the cellular membrane; in contrast, treatment with clopidogrel caused internalization of EGFR. Clop, clopidogrel.
Mol Carcinog, 2018, 57(12):1690-1697. Clopidogrel (SR-25990C) Bisulfate purchased from Selleck.
Purity & Quality Control
Choose Selective P2 Receptor Inhibitors
|Description||Clopidogrel Bisulfate (SR-25990C, Clopidogrel hydrogen sulfate, Iscover, Plavix) is an oral, thienopyridine class antiplatelet agent.|
Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes.  Clopidogrel (1 μM) also inhibits EGF-stimulated EGF receptor, PERK expression, and cell proliferation in RGM-1 cells (P<0.05), and causes much less inhibition of EGF-stimulated cell proliferation in EGF receptor over-expressed RGM-1 cells than in RGM-1 cells (22% vs. 32% reduction).  Clopidogrel increases blood vessel number, reduces polymorphonuclear count and decreases attachment and bone loss, also decreases osteoclast number in rats submitted or not to periodontal repair. Clopidogrel decreases CXCL4, CXCL12 and PDGF content compared with saline-treated rats, without affecting CXCL5. 
|In vivo||Clopidogrel (2mg and 10mg/kg/day) significantly decreases ulcer-induced gastric epithelial cell proliferation and ulcer-stimulated expressions of EGF receptor and phosphorylated extracellular signal-regulated kinase (PERK) at the ulcer margin of rats.  Clopidogrel improves endothelial function and NO bioavailability in rats with congestive heart failure. Clopidogrel-treated Congestive heart failure (CHF) rat displays enhances phosphorylation of AKT and eNOS.  The clopidogrel/aspirin combination shows only additive-type effects on bleeding time prolongation induced by ear transection in the rabbit, therefore showing that combined inhibition of cyclooxygenase and ADP's effects provide a marked enhanced antithrombotic efficacy. |
-  Laine L, et al. Am J Gastroenterol, 2010, 105(1), 34-41.
-  Luo JC, et al. Eur J Pharmacol, 2012, 695(1-3), 112-119.
-  Coimbra LS, et al. J Clin Periodontol, 2014, 41(3), 295-302.
|In vitro||DMSO||83 mg/mL (197.66 mM)|
|Water||78 mg/mL warmed (185.75 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Synonyms||Clopidogrel hydrogen sulfate, Iscover, Plavix|
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03774394||Recruiting||Drug: Clopidogrel|Drug: Clopidogrel active metabolite||Chronic Kidney Disease (CKD)|Type 2 Diabetes Mellitus (T2DM)|Coronary Artery Disease (CAD)||University of Florida|Scott R. MacKenzie Foundation||August 22 2019||Phase 4|
|NCT03039205||Completed||Drug: Clopidogrel|Drug: Ticagrelor||Platelet Aggregation|Adenosine|Coronary Artery Disease|Kidney Dysfunction|Antiplatelet Therapy||University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo||November 7 2017||Phase 2|
|NCT02185534||Completed||Drug: Clopidogrel||Bioequivalence AUC Cmax Pharmacokinetics||AstraZeneca||August 2014||Phase 1|
|NCT01503658||Completed||Drug: Clopidogrel+Aspirin||Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel|Influence of Aspirin on the Pharmacokinetics/Pharmacodynamics of Clopidogrel||Seoul National University Hospital||January 2012||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.